Infants born to women who were treated with antibodies against tumor necrosis factor alpha (TNF alpha) during pregnancy have detectable levels of antibodies until 12 months of age, according to the results of a recent study published in the journal Gastroenterology.

In this Mayo Clinic video, learn more about the increased risk for adverse birth outcomes in women with inflammatory bowel disease (IBD) with Dr. Sunanda Kane, M.D.

Read full article here: http://bit.ly/1Wj5i8v

Learn more about IBD here: http://bit.ly/learnIBD